动脉化疗栓塞联合增强放射治疗治疗难治性骨盆软骨瘤的疗效分析

目的探讨动脉化疗栓塞联合增强放射治疗治疗难治性骨盆软骨瘤的效果。方法选取2011年1月至2013年12月间收治的难治性骨盆软骨瘤患者70例,根据治疗方法不同分为接受动脉化疗栓塞联合增强放射治疗的观察组和接受全身化疗联合增强放射治疗的对照组,每组35例,比较两组患者的存活情况、不良反应以及血管新生指标。结果观察组患者的1、2、3年生存率(91.4%、80.0%和60.0%)均明显高于对照组,其发生肾功能损伤、肝功能损伤、口腔黏膜炎、骨髓抑制和胃肠道反应的例数少于对照组,血管内皮生长因子(VEGF)A、VEGFB和VEGFC水平[(82.34±11.26)ng/ml、(77.92±9.54)ng/ml、(52.35±7.33)ng/ml]明显低于对照组。结论动脉化疗栓塞联合增强放射治疗有助于提高难治性骨盆软骨瘤患者的远期生存率,减少不良反应的发生率,并控制肿瘤血管新生,是治疗难治性骨盆软骨瘤的理想方法。

Application effect of arterial chemoembolization combined with enhanced radiotherapy in treating refractory pelvic cartilage tumor

Objective To study the effect of arterial chemoembolization combined with enhanced radiotherapy in treating refractory pelvic cartilage tumor. Methods Refractory pelvic cartilage tumor patients in our hospital from January 2011 to December 2013 were enrolled and divided into observation group given arterial chemoembolization combined with enhanced radiotherapy and control group given systemic chemotherapy combined with enhanced radiotherapy. Then survival condition, adverse reaction and angiogenesis index were compared. Results Observation group patients＇ 1 year survival rate, 2 year survival rate, 3 years survival rate （91.4% ,80. 0% ,60. 0% ）were higher than those of control group, cases of renal injury, liver function damage, oral mucositis, bone marrow suppression, gastrointestinal reactions of observation group were less than the control group, angiogenesis index VEGFA, VEGFB and VEGFC [ （82. 34 ± 11.26）ng/ml, （77. 92 ± 9. 54） ng/ml, （52. 35 ±7. 33） ng/ml were lower than control group. Conclusions Arterial chemoembolization combined with enhanced radiotherapy are ideal therapy in treating refractory pelvic cartilage tumor for it can improve long-term survival rate, reduce adverse reaction and control tumor angiogenesis.